The role of hepcidin as a non-invasive biomarker for NASH or NAFLD has generated considerable interest since some studies have shown variable increase in its serum levels in patients with NAFLD and variable correlations with hepatic inflammation and histological severity [25–27]. This evidence concerns the gene HAMP and metabolic dysfunction-associated steatohepatitis.